AngioDynamics (NASDAQ:ANGO) Given New $19.00 Price Target at HC Wainwright

AngioDynamics (NASDAQ:ANGO) had its target price hoisted by HC Wainwright from $16.00 to $19.00 in a research report sent to investors on Wednesday, Marketbeat.com reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

ANGO has been the subject of several other research reports. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. Zacks Research cut shares of AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Finally, Canaccord Genuity Group boosted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

AngioDynamics Stock Performance

ANGO opened at $14.47 on Wednesday. AngioDynamics has a one year low of $8.36 and a one year high of $14.80. The company has a market cap of $597.90 million, a P/E ratio of -16.63 and a beta of 0.34. The business’s 50-day simple moving average is $12.14 and its 200-day simple moving average is $11.33.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, analysts predict that AngioDynamics will post -0.26 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its position in AngioDynamics by 9.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after buying an additional 22,658 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of AngioDynamics by 267.1% in the 1st quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after acquiring an additional 34,054 shares during the period. Legal & General Group Plc lifted its stake in shares of AngioDynamics by 279.5% in the 2nd quarter. Legal & General Group Plc now owns 12,353 shares of the medical instruments supplier’s stock worth $123,000 after acquiring an additional 9,098 shares during the period. Rhumbline Advisers boosted its holdings in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of AngioDynamics by 15.8% during the second quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after acquiring an additional 13,217 shares during the period. 89.43% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported Q4 adjusted EPS of -$0.07, better than the -$0.11 estimate, while revenue of $86.61 million also topped forecasts. Article Title
• Positive Sentiment: Management said fiscal 2026 was a record year, with continued execution driving Med Tech growth and full-year profitability, which can support a stronger investor narrative. Article Title
• Positive Sentiment: AngioDynamics raised its fiscal 2027 revenue outlook to $336 million-$341 million, above consensus, signaling confidence in continued top-line growth. Article Title
• Positive Sentiment: HC Wainwright increased its price target on ANGO from $16 to $19 and reiterated a buy rating, implying further upside if execution continues. Article Title
• Neutral Sentiment: Analysts now broadly expect AngioDynamics to keep improving, but profitability remains negative and the company’s FY2027 EPS guidance is still below consensus, so investors may want to watch whether margin gains continue.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.